DT-216P2 + Saline
Phase 1Recruiting 1 views this week 0 watching💤 Quiet
Interest: 30/100
30
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Friedreich Ataxia
Conditions
Friedreich Ataxia
Trial Timeline
Feb 1, 2025 → Dec 1, 2025
NCT ID
NCT06772870About DT-216P2 + Saline
DT-216P2 + Saline is a phase 1 stage product being developed by Design Therapeutics for Friedreich Ataxia. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06772870. Target conditions include Friedreich Ataxia.
What happened to similar drugs?
0 of 9 similar drugs in Friedreich Ataxia were approved
Approved (0) Terminated (0) Active (9)
Hype Score Breakdown
Clinical
6
Activity
15
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06772870 | Phase 1 | Recruiting |
Competing Products
20 competing products in Friedreich Ataxia